| 000 | 01010 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250513201424.0 | ||
| 264 | 0 | _c20000128 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0098-7484 | ||
| 024 | 7 |
_a10.1001/jama.283.2.250 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarkowitz, M | |
| 245 | 0 | 0 |
_aResistance, fitness, adherence, and potency: mapping the paths to virologic failure. _h[electronic resource] |
| 260 |
_bJAMA _cJan 2000 |
||
| 300 |
_a250-1 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Editorial | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHIV _xdrug effects |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aViral Load |
| 773 | 0 |
_tJAMA _gvol. 283 _gno. 2 _gp. 250-1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jama.283.2.250 _zAvailable from publisher's website |
| 999 |
_c10589682 _d10589682 |
||